RYBELSUS's oppositions filed in EPO
RYBELSUS Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8536122 | NOVO | Acylated GLP-1 compounds |
Mar, 2026
(1 year, 10 months from now) | |
| US8129343 | NOVO | Acylated GLP-1 compounds |
Dec, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9278123 | NOVO | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Dec, 2031
(7 years from now) | |
| US10960052 | NOVO | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid |
Dec, 2031
(7 years from now) | |
| US10086047 | NOVO | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Dec, 2031
(7 years from now) | |
| US11382957 | NOVO | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Dec, 2031
(7 years from now) | |
| US11759501 | NOVO | Compositions of GLP-1 peptides and preparation thereof |
Mar, 2033
(8 years from now) | |
| US10933120 | NOVO | Compositions of GLP-1 peptides and preparation thereof |
Mar, 2033
(8 years from now) | |
| US11759502 | NOVO | Compositions of GLP-1 peptides and preparation thereof |
Mar, 2033
(8 years from now) | |
| US11759503 | NOVO | Compositions of GLP-1 peptides and preparation thereof |
Mar, 2033
(8 years from now) | |
| US10278923 | NOVO | Oral dosing of GLP-1 compounds |
May, 2034
(10 years from now) | |
Rybelsus is owned by Novo.
Rybelsus contains Semaglutide.
Rybelsus has a total of 11 drug patents out of which 0 drug patents have expired.
Rybelsus was authorised for market use on 20 September, 2019.
Rybelsus is available in tablet;oral dosage forms.
Rybelsus can be used as method of treating type 2 diabetes mellitus.
Drug patent challenges can be filed against Rybelsus from 05 December, 2021.
The generics of Rybelsus are possible to be released after 02 May, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 20, 2022 |
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| M(M-252) | Jan 16, 2023 |
Drugs and Companies using
SEMAGLUTIDE ingredient
NCE-1 date:
05 December, 2021
Market Authorisation Date:
20 September, 2019Treatment:
Method of treating type 2 diabetes mellitusDosage:
TABLET;ORAL
More Information on Dosage
RYBELSUS family patents
